These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 33745080)
1. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080 [TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis. Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. Zhang M; Song J; Yang H; Jin F; Zheng A Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis. Villacampa G; Navarro V; Matikas A; Ribeiro JM; Schettini F; Tolosa P; Martínez-Sáez O; Sánchez-Bayona R; Ferrero-Cafiero JM; Salvador F; Papakonstantinou A; Prat A; Oliveira M; Pascual T JAMA Oncol; 2024 Oct; 10(10):1331-1341. PubMed ID: 39207778 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis. Liang X; Chen X; Li H; Li Y Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447 [TBL] [Abstract][Full Text] [Related]
6. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis. Villacampa G; Tolosa P; Salvador F; Sánchez-Bayona R; Villanueva L; Dienstmann R; Ciruelos E; Pascual T Cancer Treat Rev; 2022 Mar; 104():102352. PubMed ID: 35144055 [TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis. Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J Front Immunol; 2023; 14():1206689. PubMed ID: 37377959 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis. Mittal N; Singh S; Mittal R; Kaushal J; Kaushal V J Cancer Res Ther; 2022; 18(6):1754-1765. PubMed ID: 36412440 [TBL] [Abstract][Full Text] [Related]
9. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142 [TBL] [Abstract][Full Text] [Related]
10. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis. Qi Y; Yan X; Wang C; Cao H; Liu G Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783 [No Abstract] [Full Text] [Related]
12. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants. Wu Q; Wu C; Xie X J Immunother; 2023 Feb-Mar 01; 46(2):29-42. PubMed ID: 36378154 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Li Y; Xing L; Li F; Liu H; Gan L; Yang D; Wang M; Yin X; Li H; Ren G Front Oncol; 2021; 11():657634. PubMed ID: 34912699 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. Cui W; Luo Q; Sun SL; Xu JL; Gu H Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848 [TBL] [Abstract][Full Text] [Related]
16. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345 [TBL] [Abstract][Full Text] [Related]
18. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis. Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G Cells; 2022 Jun; 11(12):. PubMed ID: 35740985 [TBL] [Abstract][Full Text] [Related]
19. Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: A systematic review and meta-analysis. Gao X; Zhu Y; Wang P; Yu L; Ruan S; Shen M; Zhang K Cancer Med; 2023 Dec; 12(24):21873-21884. PubMed ID: 38063264 [TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis. Wei Y; Wu Y; Luo Y; Ma F Crit Rev Oncol Hematol; 2024 Apr; 196():104309. PubMed ID: 38423376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]